AGRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AGRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Agile Therapeutics has the Momentum Rank of 0.
Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of Agile Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott M Coiante | officer: Chief Financial Officer | 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540 |
Josephine Torrente | director | 101 POOR FARM ROAD, PRINCETON NY 08540 |
Sandra Carson | director | C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540 |
John W Hubbard | director | 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540 |
Fischer Seth H.z. | director | C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Sharon Surrey Barbari | director | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Amy Welsh | officer: Chief Commercial Officer | 500 COLLEGE ROAD EAST, SUITE 310, C/O AGILE THERAPEUTICS, INC., PRINCETON NJ 08540 |
Alfred Altomari | director, officer: Chief Executive Officer | C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Dennis Reilly | officer: Chief Financial Officer | 600 COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Jason Butch | officer: Principal Accounting Officer | 101 POOR FARM ROAD, PRINCETON NJ 08540 |
Paul Korner | officer: Sr. VP & Chief Medical Officer | C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555 |
Abhijeet J Lele | director, See remarks | C/O EP MEDYSTEMS, 575 RTE 73 N, WEST BERLIN NJ 08091 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By Marketwired • 07-03-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 08-26-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 10-04-2023
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.